Portland – October 06, 2026 -- Headlands Research - Summit Portland is marking 50 years of operation in 2026, having contributed clinical research to every FDA-approved class of Alzheimer's disease medication brought to market since 1993. The site, founded in 1976, has conducted more than 500 clinical trials in partnership with pharmaceutical companies and contract research organizations (CROs).
Grand Rapids – September 16, 2026 -- Headlands Research has established a new clinical trial site in Grand Rapids, Michigan, led by board-certified rheumatologist Eric Slavin, MD, FACP, FACR, expanding the network's capacity for rheumatology, autoimmune disease, and cardiometabolic trials in the Midwest.
Headlands Research - Grand Rapids is currently under development and expected to open later in 2026. The site will focus on rheumatology, bone and joint conditions, and autoimmune and inflammatory diseases, while also conducting studies in general medicine, chronic kidney disease, obesity, hypertension, hyperlipidemia, and vaccines.
Kyle Burtnett, CEO of Headlands Research, said sponsor demand for rheumatology and autoimmune disease trials continues to climb, positioning the new site to address that gap in the Midwest market.